Best Cancer Doctors in SS SPARSH Hospital (Mysore Road) Bangalore, India

Dr. Mansi Khanderia is a dedicated medical oncologist in RR Nagar, Bangalore, who combines rigorous training, international exposure, and strong academic credentials with a compassionate, patient-centered approach to comprehensive cancer care. Her clinical practice emphasizes evidence-based, multidisciplinary care and quality-of-life optimization for cancer patients and families. An active anti-tobacco advocate, Dr. Mansi participates in policy dialogues and cancer control initiatives that address disparities in low- and middle-income countries.

Why Choose Dr. Mansi Khanderia?

• Comprehensive Medical Oncology Expertise: She is experienced in treating solid tumors (breast, GI, lung, gynecologic cancers) as well as hematologic cancers, delivering tailored systemic therapy plans that align with current international guidelines.
• Advanced Systemic and Supportive Therapies: Dr. Mansi is proficient in chemotherapy, targeted therapy, immunotherapy, and intraperitoneal therapies, with a strong focus on supportive oncology and symptom control to minimize treatment-related morbidity.
• Special Interest in Women’s Oncology and AYA Cancers: She has focused training and clinical interest in breast and gynecologic cancers, and in AYA malignancies (lymphomas, sarcomas, germ cell tumors), offering age-appropriate, multidisciplinary care.
• International Exposure and Fellowship Training: Dr. Mansi has been awarded a scholarship for an international travel fellowship in breast cancer at Memorial Sloan Kettering Cancer Center (MSKCC), New York, and has participated in ESMO preceptorships, which ensure her practice aligns with global standards.
• Strong Academic Credentials and National Recognition: She topped the national medical oncology examinations and was awarded the PRESIDENT NBE National Gold Medal in Medical Oncology. She is ESMO-certified and a certified palliative care physician, indicating both clinical expertise and a commitment to holistic care.

Dr. Sunil Navalgund is one of the best Surgical Oncologists in India, with an overall experience of 18 years. He has a substantial amount of experience in minimally invasive and robotic cancer surgeries. He is knowledgeable about cutting-edge cancer treatment technologies and expertly uses them to provide patients with the finest results.

Why Choose Dr. Sunil Navalgund?

• Extensive Years of Experience: Dr. Navalgund holds over 18 years of experience as a comprehensive surgical oncologist and a cancer specialist. He utilises and integrates many ultramodern technological advancement techniques for his patients so that they can gain the maximum possible profit out of his specialities and can lead a healthy life. 
• Professional Expertise: He holds expertise in various fields of oncology procedures, such as gynaecological cancer treatment, breast cancer management, head and neck tumour/cancer surgery, stem cell transplantation, lung cancer treatment, giant cell tumour treatment, cancer treatment, etc. 
• Specialised Expertise: Apart from the basic oncology procedures, Dr. Sunil Navalgund is an expert in other surgical procedures such as minimally invasive onco surgeries, VATS thoracic surgeries, hepatobiliary and pancreatic surgery functions, and organ-preserving surgeries. 
• Additional Aptitude: He was an assistant professor at MVJ Medical College and Dr. B.R. Ambedkar Medical College, Bangalore, as well as a speciality surgical registrar at his former school, TMH. To provide maximum benefits to his patients, he stays up to date on all new and cutting-edge technologies, such as organ and function preservation techniques, sphincter-saving surgery for rectal cancer, oncoplasty for breast cancer, and laparoscopic and robotic surgeries.
• Academic Qualification: He is highly qualified as an oncologist, having pursued MBBS from BM Patil Medical College, Bijapur, in 2007, followed by MS (General Surgery) from Bellary in 2011 and MCh (Surgical Oncology) from Tata Memorial Hospital & R.C. Mumbai, Homi Baba National Institute, in 2016.